title: Lack of BDNF expression through promoter IV disturbs expression of monoamine genes in the frontal cortex and hippocampus.
abstract: Brain-derived neurotrophic factor (BDNF) is implicated in the pathophysiology of psychiatric conditions including major depression and schizophrenia. Mice lacking activity-driven BDNF expression through promoter IV (knock-in promoter IV: KIV) exhibit depression-like behavior, inflexible learning, and impaired response inhibition. Monoamine systems (serotonin, dopamine, and noradrenaline) are suggested to be involved in depression and schizophrenia since many of the current antidepressants and antipsychotics increase the brain levels of monoamines and/or act on monoamine receptors. To elucidate the impact of activity-driven BDNF on the monoamine systems, we examined mRNA levels for 30 monoamine-related genes, including receptors, transporters, and synthesizing enzymes, in KIV and control wild-type mice by using quantitative reverse-transcription polymerase chain reaction (qRT-PCR). mRNA levels were measured in the frontal cortex and hippocampus, which are regions related to depression and schizophrenia and where promoter IV is active. The frontal cortex of KIV mice showed reduced levels of mRNA expression for serotonin receptors 1b, 2a, and 5b (5HTR1b, 5HTR2a, 5HTR5b), dopamine D2 receptors (DRD2), and adrenergic receptors alpha 1a and 1d (AdRα1a and AdRα1b), but increased levels for serotonin synthesizing enzyme, tryptophan hydroxylase (TPH), and dopamine D4 receptor (DRD4) when compared to control wild-type mice. The hippocampus of KIV mice showed decreased levels of 5HTR5b. Our results provide causal evidence that lack of promoter IV-driven BDNF disturbs expression of monoaminergic genes in the frontal cortex and hippocampus. These disturbed expression changes in the monoamine systems may mediate the depression- and schizophrenia-like behavior of KIV mice. Our results also suggest that antidepressant and antipsychotic treatments may actually interfere with and normalize the disturbed monoamine systems caused by reduced activity-dependent BDNF, while the treatment responses to these drugs may differ in the subject with reduced BDNF levels caused by stress and lack of neuronal activity.
authors.affiliation: Department of Pharmacology, University of Tennessee Health Science Center, Memphis, TN, USA. Electronic address: ksakata@uthsc.edu.
authors.forename: K
authors.initials: K
authors.lastname: Sakata
authors.affiliation: Department of Pharmacology, University of Tennessee Health Science Center, Memphis, TN, USA.
authors.forename: S M
authors.initials: SM
authors.lastname: Duke
mesh_terms: D000818:Animals; D015306:Biogenic Monoamines / Q000378:metabolism*; D019208:Brain-Derived Neurotrophic Factor / Q000235:genetics*; D005260:Female; D005625:Frontal Lobe / Q000378:metabolism*; D006624:Hippocampus / Q000378:metabolism*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D011401:Promoter Regions, Genetic
chemical_list: D015306:Biogenic Monoamines; D019208:Brain-Derived Neurotrophic Factor
keywords: AdR; BDNF; Brain-derived neurotrophic factor; Ct; DAT; DRD2; DRD4; EDTA; EPSC; FC; FDR; HIP; IPSC; KIV; NET; SE; SSRI; TH; TPH; WT; adrenergic receptor; cycle threshold; dopamine D2 receptor; dopamine D4 receptor; dopamine transporter; ethylenediaminetetraacetic acid; excitatory postsynaptic current; false discovery rate; frontal cortex; gene expression; hippocampus; inhibitory postsynaptic current; knock-in promoter IV; monoamine systems; norepinephrine transporter; promoter IV; qRT-PCR; quantitative reverse-transcription polymerase chain reaction; selective serotonin reuptake inhibitor; standard error of mean; tryptophan hydroxylase; tyrosine hydroxylase; wild-type